If clinical markers are not improving after an adequate trial period at therapeutic doses, the prescribing clinician should reassess the treatment plan and consider whether retatrutide remains the most appropriate option
GHRPs, including GHRP-2, can stimulate the release of adrenocorticotropic hormone (ACTH) and consequently cortisol , and can also raise prolactin , particularly at higher doses
Its this weight gain that is bothering me. Arnold, who works for an HVAC company, would really like to go back on exanetide, but as is the case with so many other patients who have experienced benefits from GLP-1 receptor agonists, shes finding that its too expensive to do so
If you take thyroid hormone for hypothyroidism, L-carnitine can blunt thyroid effects at the tissue level
American Journal of Physiology / Endocrinology (2006) 4
See our privacy policy for details on how we handle your information